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INCIDENCE OF BACTEROBILIA  IN PATIENTS WITH
BILIARY OBSTRUCTION IN A TERTIARY CARE CENTER
ABSTRACT
OBJECTIVES ;
                  Bacterobilia  is  commonly  observed in  patients  with  obstructed
biliary  system   and is  usually  asymptomatic .Routine  bile  culture  obtained
during ERCP can  help in  predicting  dreaded  complications  like  cholangitis
.We studied  30  consecutive bile samples  and analysed  the incidence  of
bacterobilia comparing  benign  and  malignant  etiology .
METHODS ;
      30  Consecutive  patients  with  biliary obstruction   who have undergone
ERCP at our hospital  were studied.Study population  included  13 males  and
17 females .23 cases were of  benign etiology .7 were malignant .After
successful  biliary  cannulation ,bile was obtained  and sent for  microbiological
analysis.
RESULTS ;
Bile cultures were  positive  in  16  patients .10 of them    had  benign
etiology  .6 of them were malignant .Organisms grown  are mainly  gram
negative with  Klebsiella in most  of  them .Response to  cephalosporins  were
good   and resistance  to  ciprofloxacin  was observed   .
CONCLUSIONS ;
This study confirms the importance of  obtaining  routine  bile  sample
during ERCP   in  obstructed  biliary system  to predict   and prevent  dreaded
complications like cholangitis  .
KEY WORDS: Bacterobilia, Bile culture, Obstructive
jaundice,Antibiotics.
1INTRODUCTION
Bile in individuals with normal biliary  tract  is sterile. Presence of
biliary obstruction leads to bacterial colonisation of bile. Ascending
infection from duodenum and or bacterial translocation from portal vein
are the likely sources of infection .Increase in the common bile duct
pressure due to obstruction in the presence of infected bile promotes
bacterial reflux into lymphatics and hepatic sinusoids resulting in
cholangitis.
Studies that included both benign and malignant causes of biliary
obstruction confirmed that bacterobilia  is more common in benign biliary
obstruction than malignant biliary obstruction. This is probably due to
intermittent nature of benign obstruction facilitating bacterial
colonisation.
RISK FACTORS FOR BACTEROBILIA
The risk factors or bacterobilia proportionately varies with
underlying pathology .The most common causes are,
1. Common bile duct stones,
2. benign biliary strictures and
3. malignant strictures.
2Other risk factors for bacterobilia  are
1. Age >70 years ,
2. Diabetes mellitus and
3. previous biliary intervention .
Microbial flora commonly seen in infected bile  include  E.coli,
Klebsiella, Enterococci, proteus ,salmonella and  pseudomonas.
In this study, we evaluated the incidence of bacterobilia in  patients
who  underwent  ERCP  for  obstructed  biliary  system in  our  centre.We
also  evaluated   the   possible   risk   factors   for   bacterobilia    in   such
cases .We  also compared   the  incidence  of  bacterobilia  in  benign  and
malignant   conditions   presenting   with   biliary   obstruction.We  also
studied  the  microbiological  pattern  of  bile  in  such  cases  and  their
antibiotic  sensitivity.
3REVIEW OF LITERATURE
Extra-hepatic  biliary obstruction occurs as a result of  anatomical
obstruction to common bile duct and,common hepatic duct. Causes
include  calculi, benign and malignant tumours, and benign strictures
including  primary sclerosing cholangitis.
PATHOPHYSIOLOGY OF OBSTRUCTIVE  JAUNDICE
Obstruction to bile flow increases biliary pressure with dilatation of
biliary tree .There is regurgitation of bile into the circulation and hepato-
cellular damage. The degree of rise in biliary pressure depends upon the
secreting capacity of  the hepatocytes and ductular cells and distensibility
of the biliary tract.
Some bile reaches the circulation  via lymphatics .Paracellular flow
is another route .Bile passage also occurs across the hepatocyte in
intracellular vacuoles .Only a small rise in biliary pressure  is necessary
for regurgitation  of bile into the circulation. Bile duct obstruction results
in numerous changes in the  hepatic  structure and function.
The cause of hepatocellular injury  is likely to be multifactorial.
Retained bile salts have detergent properties and are cytotoxic in vitro.
The toxicity increases with increasing hydrophobicity. Monohydroxy bile
4salts such as lithocholate are more toxic than dihydroxy bile salts such as
chenadeoxycholate  or deoxycholate  which in turn are more toxic than
trihydroxy bilesalts  such as cholate.
Copper which is normally excreted in bile is retained in patients
with cholestasis.Mitochondrial respiratory enzyme activity and
ketogenesis are impaired  and take several  weeks to recover after relief
of obstruction .Hepatic mitochondrial response to oral glucose is impaired
in patients with  obstructive jaundice  and relates to survival.
Hepatic transport process appears to remain intact. After relief of
bile  duct  obstruction  ,bile  acid  transport   into  bile  begins   virtually
immediately  and the serum non –sulfated bile  acid  concentration  falls
rapidly to normal.
In general, after relief of obstruction,serum bilirubin  concentration
falls  with  a  half  life  of  approximately  7  days.  Persistent  hyper
bilirubinemia  is seen when there is cholangitis, partial obstruction to
drainage ,or when there are hepatic metastasis.
During prolonged obstruction ,serum albumin level falls  even in
the absence of sepsis.
5SYSTEMIC EFFECTS
Fatigue is common with prolonged cholestasis. The exact
mechanism  is not clear. Alteration in central  neurotransmission  is
postulated as  one  of  the  causes.
Itching is common   with prolonged cholestasis and  it usually
disappears within few days of  biliary decompression. Elevated serum
bile acids  and endogenous opioid peptides are  probable mechanisms
involved.
Cardio-vascular complications are subclinical .Reduced peripheral
vascular resistance  is common.
Exaggerated response to volume depletion is common ,though the
resting blood pressure is unaffected.
Bile acids have a negative chronotropic effect. Jaundice  induced
cardiomyopathy  can occur.
Acute tubular necrosis is a very common renal complication of
obstructive jaundice particularly after surgery or any
intervention1,2,3{8%}.
6Haemorrhagic gastritis,anorexia, weight loss, hypoalbuminemia,
impaired wound healing ,are other complications reported.
Absence of bile acids in the intestinal lumen impair the absorption
of fat because of lack of miscelle formation. Plasma free cholesterol
,phospholipids and triglycerides are elevated in patients with obstructive
jaundice 4.
Bone pain with fractures occur in patients with prolonged
cholestasis and osteomalacia  is a risk5.
Bleeding tendencies are  common. Low-grade DIC  elevated FDP
levels  are seen. Platelet functions are impaired.
BILIARY OBSTRUCTION –CLINICAL FEATURES
Fever, jaundice abdominal pain are common features of biliary
obstruction. Fever is more common with choledocholithiasis. When CBD
stones are present, bacteria are usually seen in the bile .Ductal obstruction
increases the biliary pressure  and infected bile  enters the circulation
with systemic signs of sepsis.
Bile from patients with malignant  obstruction  is usually sterile.
So, fever is rare except in patients who have been treated with endoscopic
7or surgical stenting. This is  because, bacteria adheres to the stent, bile is
colonized  and stent blockage results in systemic sepsis6.
Pain is more common with stone disease but occur rarely in
malignant obstruction.
Pruritus is more common with malignant obstruction and intra-
hepatic cholestasis .Itching is rare with  calculous obstruction  because
obstruction  is rarely complete  and may not be sufficiently prolonged to
cause retention of pruritic agents. Relief of obstruction is followed by loss
of  itching   in  a  few  days.  Weight  loss  is  more  common  with  malignant
obstruction  although it can occur in benign obstructive conditions with
prolonged cholestasis.
History of previous cholecystectomy should raise the possibility of
retained  common  bile  duct  stone.  If  surgery  is  recent  and  followed   by
abnormal  drainage  of  bile  through  the  wound  or  drain  ,a  traumatic  bile
duct stricture should be suspected.
Drug history is useful in patients with cholestasis. History of
inflammatory bowel disease should raise the possibility of  primary
sclerosing cholangitis.
8History of colonic malignancy in the past with those presenting
with biliary obstruction leads to the suspicion of  hepatic metastasis  or
biliary obstruction from lymph node involvement.
EXAMINATION
Examination should focus on jaundice, scratch marks, body mass
index, signs of chronic liver disease to suggest long standing intrahepatic
cholestasis, Liver may be palpable. Splenomegaly is usually seen with
liver disease except in  splenic  vein  block  complicated by pancreatic
malignancy.
A palpable gallbladder suggests malignant obstruction to distal
CBD{ Courvoisier law .}
Lab  investigations  should include CBC, urea, creatinine,
electrolytes, LFT and prothrombin time. Leucocytosis  suggests
cholangitis .Impaired renal function, hyponatremia, hypokalemia,
prolonged prothrombin time, abnormal LFT  with elevated serum
bilirubin, serum alkaline phosphatase    and  GGT are other  abnormalities
seen.
When  there  is  acute  obstruction  of  bile  duct, serum AST and
ALT levels are very  high  reaching   upto  30 times  normal.
9IMAGES ;
May be classified into non-invasive and  invasive techniques .
Ultra-sound  abdomen  is useful in detecting  the  site of  obstruction  in
2/3 rd  of  cases and cause of obstruction  in  1/3 rd  of cases.
MRCP is valuable  in delineating  ductal anatomy  and serves as  a
roadmap  for  further  work-up.
Invasive  procedures  include  ERCP and  PTC .The advantage of
ERCP is  that it serves both  diagnostic  and  therapeutic purposes.
TREATMENT
Hydration and maintenance  of  fluid  balance  is ideal. Correction
of  coagulopathy  with vitamin –k injection is useful. Antibiotics  to
combat  infection  is needed.
Management of  pruritus  include  use of bile acid  sequestrants,
opiate  antagonists, rifampin or antihistaminics. Biliary  decompression
with  prophylactic   stenting   is  indicated   in   all  cases  of   biliary
obstruction. Endoscopic  sphincterotomy  with removal of stone  from
the  common  bile duct helps  in   fastening  recovery  from  obstructive
jaundice.
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BACTEROBILIA   IN  OBSTRUCTIVE  JAUNDICE
Bacteria  may  enter  the  biliary  tract  by  two  routes.
         1. Hematogenous9,10   and
          2. Retrograde 11 .
The  hematogenous   route   involves   the   translocation  of   enteric
bacteria  across  the  bowel  wall  to  portal  vein, hepatic  sinusoids  and
via  the  space  of  Disse  into bile12. For the  retrograde route, duodenal
bacteria  migrate  through  the  ampulla  and  enter  the  biliary  system13 .
In a healthy  biliary  tract, there  are  anatomical  barriers  to  both
these  routes .The  tight  junctions  between  hepatocytes   prevent
bacterial  entry  into  bile  and  competence  of  sphincter  of  Oddi  bans
the  retrograde  route.
Additional   anti-bacterial   protection   is   provided   by   the
physiology  of   the  bile   and  the  biliary  system. Immunoglobins  are
excreted   in  to   the   bile   predominantly   IgA   and   may   bind   the
bacteria14.Bile   salts   have   antibacterial   action   demonstrable   in   vitro
15.Finally  flow  of  bile  flushes   any  contaminating  bacteria  from  the
biliary  system   constantly.
11
Diseases   of   the   biliary   tract   circumvents   or   negates   these
protective  mechanisms  and  results  in  the  presence  of  bacteria  in  the
bile   .{   BACTEROBILIA    }   Obstruction   of   biliary   system   from
either  benign  or  malignant  cause  has  marked  effect  on  the  anti –
bacterial  defence  mechanisms .
Obstruction   reduces   IgA production   and   prevents   flushing   of
bacteria20. It  increases  the  translocation  of  gut  flora  in to  the  portal
vein21. It  reduces  Kupfer  cell  function22. It disrupts  the  tight  junctions
between  the  hepatocytes23. Bacterobilia  is  more  common  with  benign
obstruction   than   malignant   obstruction.  This   is   probably   due   to
partial or  intermittent  nature  of  benign  obstruction32,facilitating
bacterial  colonisation. This  implies  that  the  retrograde  bacterial
colonisation  is  more  important  than  the  hematogenous  route .
Bacterobilia   varies  with  underlying  pathology.
Common bile duct  stones 24-29 -70 -80%
         Benign  biliary  stricture24,25    -85%
          Malignant  stricture 30,31        - 30 %
Other  risk  factors  for  bacterobilia   are
          Obstructive  jaundice
12
          Age  > 70
         Diabetes mellitus
.       orthotopic   liver  transplantation .
      Corticosteroid treatment   and
        Previous  biliary  intervention.
Bacterial  flora  almost  always   contain  enteric organisms
predominantly  gram  negative  bacilli .
E.coli   --55%
Klebsiella -20 -30 %
Proteus –5 %
Salmonella -0- 5 %
Pseudomonas39,40  0 – 25  %    wide range  exists may  reflect  prior
instrumentation   of  the  biliary  tract  or  prior  antibiotic usage.
Gram  positive  bacteria   -  mostly  enterococci   -15 -40 %
Anaerobic  organisms     -bacteroides    1 – 20 %
                                                      Clostridium   5 -15 %
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It  is  noticeable  that  bacterobilia  is  found  in  patients  without
clinical   sepsis. Once  biliary  pressure  is  raised  ,regurgitation  of  bile
in to  systemic  circulation  occurs .The  biliary  contents  reflux  into
sinusoids   when  biliary  pressure  rises  to  25 cm  of water .
Bile   culture   is   superior   to   blood   culture   in   detecting
cholangitis. The  high  sensitivity of  bile  culture  is   plausible  because
the  material   for   microbiological   analysis   is   directly  obtained  from
the  place  where  the   inflammation  occurs.
It  is  important  to  differentiate  asymptomatic  bacterobilia  from
biliary  sepsis43-44.Polymicrobial  bacterobilia  is  usually  found  in
biliary  sepsis, though  systemic  bacteremia   is  monomicrobial .
Charcot   in  1877  described   a   triad   of   fever,  right   upper
abdominal   pain   and   jaundice.  This   triad   occurs  in  56   -   70  %  of
patients  who  have  cholangitis .The  most  severe  form  , characterized
by  the  additional  clinical  features  of  hypotension  and  alteration  of
consciousness  {Reynold  pentad ]  is  uncommon  and   occurs only  in
5  -  7 %  of  cases. Fever is  the main   symptom  which  is  found  in  90
% of  cases.  Abdominal   pain  is  common in   patients   with   cholangitis,
Unlike   the  pain   secondary   to  bile   duct   stones   in   the   absence   of
infection  it is  relatively  mild  and  intermittent  .
14
            Elderly  and  immune compromised  patients may  present  with
atypical  symptoms  and  signs .The  presence of fever ,leucocytosis and
abnormal  LFT  is  highly  suggestive  of  cholangitis  .
Broad  spectrum  antibiotics with  adequate  biliary  excretion
such  as  ampicillin-sulbactum ,piperacillin-tazobactum ,third  or  fourth
generation   cephalosporins , quinolones  and  carbapenam  are  beneficial
Antibiotics  with  enterococcal and  anaerobic  coverage may  be
added  in  patients  with  advanced  age  ,severe  disease ,a  biliary  stent
in   situ   or   prior   entero-biliary   surgery.Biliary   excretion   of   most
antibiotics   is   compromised   in   the   presence  of   biliary
obstruction.Early  biliary  decompression   is  essential   to  restore  good
biliary  excretion  of  antibiotics.
MANAGEMENT  OF  CHOLANGITIS
Initially ,supportive   therapy that  includes adequate  hydration,
correction  of  coagulopathy  and  metabolic   derangements    and
antibiotic  must  be  provided.
Medical   treatment  alone  is  effective  in  approximately  80%
of   patients.  Prompt   and   adequate   biliary   drainage   is   required   in
others  to  control  the  clinical  symptoms .
15
Antibiotics  should  be  given early  when   acute cholangitis  is
suspected, even  before  it is definitely  established to  control  bacteremia
and  sepsis.
Choice  of antibiotic  depends  on   several  considerations
including   host   factors  (renal   function,  allergic   reaction)  severity  of
disease,  local   antibiotic   sensitivity   pattern  and   presence   of   prior
biliary  intervention  or  surgery.
Broad  spectrum  antibiotics   with  adequate   biliary  excretion
such  as  ampicillin-sulbactum, piperacillin-tazobactum, quinolones ,third
or  fourth generation   cephalosporins  are preferred.
Duration   of  therapy   is   based   on   clinical   response   and
presence  of  bacteremia.For mild cases  ,treatment for 5  to  7 days  may
be   sufficient.Severe   cases   with   a   positive   blood   culture    need
antibiotic  treatment  for  at least 10 to 14  days.
Biliary   drainage   is   essential   in  patients   with   cholangitis.  It
can  be  performed by
                          1. endoscopic  method
2 .percutaneous
16
3 .surgical drainage   or
4 .multimodal  approach.
Endoscopic   approach  has  several  advantages,
1. defining   ductal  anatomy
2.  identifying   simultaneous   pathology   such   as   biliary   stricture   or
choledochal  cyst.
3. collecting  bile  for  microbiologial  study
4. providing   tissue   sampling   .
5. allowing  definitive  treatment  in most   cases and
6. less  morbidity  than  the  per  cutaneous   route  .
Endoscopic  biliary  drainage  is  the  procedure  of    choice.
Percutaneous  drainage  or  surgical  decompression   is  a  useful
alternative  when  endoscopic   treatment  is  technically  impossible  or
unsuccessful .
When ERCP  is  performed  in  the  presence  of  active  cholangitis
and   purulent   bile   ,care   must   be   taken   to   avoid   aggravating   the
17
existing   high   intraductal   pressure.  Contrast   injection   during   biliary
cannulation  should  be  minimized.
Once   deep   cannulation   is   successful,  20  to   40   ml   of   bile
should  be  aspirated  to  decompress  the  bile  duct  and to  provide  a
sample  of   bile   for   microbiological   analysis  .  Then   limited contrast
can   be   injected   to   fill   only   the   extra-hepatic    ductal   system   to
define  the  cause  and  location  of  the   obstruction  unless  intrahepatic
bile   duct   pathology  is   suspected.  Definitive   therapy   of   biliary
endoscopic   sphincterotomy  with   removal   of   stones  is  pursued   in   a
stable  patient   who  has  confirmed  bile   duct   stones .  In  an unstable
patient , every  effort  should  be  made  to  shorten  the  procedure  time
while  providing   adequate  biliary  drainage.
Definitive   therapy   can   be   performed   subsequently   once   the
general   condition   of   the   patient   is   stabilized.  Prolonging   the
procedure   to   attempt   definite   therapy   in   an   unstable   patient   may
increase   the   morbidity   and   mortality.  In   a  patient   with   severe
cholangitis, endoscopic  biliary  drainage  can  be  achieved  with  plastic
biliary   stent    or   with   nasobiliary   catheter   with   or   without   biliary
endoscopic  sphincterotomy.
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Concomittant  sphincterotomy  facilitates  the  placement  of  a
large  stent  or  multiple  stents  for  more  effective  drainage  and  with  a
minimal  risk   of stent  migration .Risk of post  sphincterotomy  bleeding
correlates significantly  with  the  presence of  acute  ascending
cholangitis, even  in  the  absence  of  coagulopathy .
Nasobiliary   drainage   provides   the   advantage   of   active
decompression   by   intermittent   or   continuous   negative   pressure
suction  and  the opportunity  for  sequential  bacterial   bile  cultures.
But  used  infrequently  because of
1. patient  discomfort
2. possibility  of   inadvertent  dislodgement  of  the  nasobiliary
catheter.
3. risk   of  kinking  with  inadequate  drainage  and
4. the  potential  for  electrolyte  disturbance  secondary  to external
diversion  of  bile.
Percutaneous   transhepatic   biliary   drainage   is    generally
reserved  for  patients  in  whom  endoscopic  method  is unsuccessful  or
who have  altered  anatomy  such  as  prior  gastric  bypass  surgery.
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Surgical   drainage   is   done   by   either  open   or   laparoscopic
common  bile   duct   exploration.  In  severely  ill   patients,  the  simplest
procedure  ( like  T-tube  placement ) should  be  performed  to  shorten
the   procedure   time.  The   option   of   definitive   therapy  can   be
determined later  when  appropriate.Because  of  the  operative  risk,
emergency  surgical  decompression  is  rarely  performed. It  is  reserved
for  patients  for  whom   both  endoscopic  and  percutaneous approach
are  unsuccessful  or  who  have  altered  anatomy  which  precludes  such
procedure.
DIAGNOSTIC  CRITERIA  AND  SEVERITY  ASSESSMENT  OF
ACUTE  CHOLANGITIS  --  TOKYO GUIDELINES
( K .Wada  et al  - journal of hepatobiliary  pancreatic  surgery51   2007
14—52-58  )
Diagnosis  is  based  on
1. history  of  biliary  disease.
2. clinical  manifestations
3. laboratory   data  indicative  of  presence  of  inflammation  and
biliary  obstruction.
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4. imaging  findings indicative  of  biliary  obstruction  and  or
evidence  of  etiology  were suitable  making  the  diagnosis  of
acute   cholangitis.
DIAGNOSTIC  CRITERIA ;
A. clinical  context and clinical  manifestation.
               1. history  of  biliary  disease
               2. fever  with or  without  chills  .
               3. jaundice
               4. abdominal  pain  -  right  upper  quadrant  or  upper
abdomen
B .Laboratory  data –
5 .evidence  of  inflammatory  response. –abnormal  WBC count,
increased  c-reactive  protein  or  other changes  indicating  inflammation.
               6.  abnormal   liver   function   tests  –increased   serum   alkaline
phosphatase, GGT, altered AST or  ALT levels.
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C .imaging  findings  --
              7 .biliary dilatation  or  evidence  of  an  etiology  suggestive of
stricture, stone, stent   etc.,
Suspected  diagnosis  -two  or  more  items  in   A.
Definite diagnosis ;--
         1. Charcot triad   ( 2+3+4 )
         2. two or more  items  in  A   and both  items  in  B and  C .
PROGNOSTIC  FACTORS  ;
Can be  divided  in to
              1.  those  related to  organ   dysfunction    and
              2. those  unrelated  to  organ  dysfunction.
Those related  to  organ  dysfunction  are
          1. shock
2. mental  confusion
3. elevated serum creatinine .
22
4. elevated BUN.
5. prolonged  prothrombin  time  .
6. hyperbilirubimemia and
7. reduced platelet  count  .
Those  unrelated  to  organ  dysfunction   are
1.    high  fever
2. leucocytosis
3. bacteremia
4. endotoxemia
5. hypoalbuminemia
6. liver  abcess
7. medical  co morbidities
8. elderly patients  >75 years  and
9. malignancy  as  etiology
23
SEVERITY  ASSESSMENT  ;
Can  be  classified  in to mild, moderate  and  severe.
Mild    --which  responds  to  medical  management.
Moderate  -which  does  not  respond  to  medical  management  but  not
having   organ  dysfunction.
Severe  cholangitis –onset  of  dysfunction  of any one of the following
organs.
1. cardio-vascular –hypotension   requiring  dopamine  infusion .
2. neurological –disturbance of  consciousness .
3. respiratory  -pao2/ Fi o2 ratio  < 300
4. kidneys -  serum creatinine  > 2.0   mg/ dl
5. liver  -PT-INR  >1.5
6. platelet count   <  1,00,000 / mcl
Elderly    patients   >75  years   old    and   patients  with   co-morbid
Illness  should be  monitored   closely.
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FACTORS THAT PREDICT MORTALITY   IN CHOLANGITIS
(Bae WK et al Korean journal ofGastroenterology 2008 )
1. Age  > 50 years
2. Female gender
3. associated  liver abscess
4. associated  cirrhosis
5. cholangitis  due to high grade malignant obstruction
6. cholangitis after trans hepatic  choledochography and
7. Acute  renal  failure
Cholangitis   due to malignant  obstruction   is  increasing  mainly
due to frequent   use  of   endoscopic   or   radiological   biliary  drainage
procedures.  One  third   of   patients  with   malignant  biliary   obstruction
had  history  of  ERCP  in the past.
However, studies  reported a high  incidence  of  bacterobilia and
fungal   colonisation    associated   with  pre  operative   biliary  drainage.
(Jethwa et al alim. pharmacology 2007) High antibiotic coverage  is
needed and may be modified  after  bile  culture report. Special cultures
for fungal  growth  should be done and managed  accordingly and
appropriately.
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AIM  OF  THE  STUDY
1 . To  evaluate   the  incidence  of  bacterobilia  in  patients  with
obstructive  jaundice  undergoing  ERCP  at  our  hospital.
2 . To  study  the  risk  factors  for  bacterobilia.
3 . To  study  the  microbiological  pattern  of  bile  in obstructed
biliary  system.
4 . To  compare  the  frequency  of  bacterobilia   in  benign  and
malignant  obstruction.
5. To  study  the  drug   sensitivity pattern  of  bacteria  grown   in
bile  culture  in  our  center.
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MATERIALS AND METHODS
PLACE  OF  STUDY:
Department  of  Digestive  Health  and  Diseases
Government  Peripheral  Hospital
Anna  nagar, Chennai.
TYPE  OF  STUDY:
Prospective ,observational and  diagnostic  study  .
PERIOD  OF  STUDY
September 2011   to February 2012 .
ETHICAL COMMITTEE:
Approval  obtained  .
CONSENT :
Informed  consent  obtained  from  all  participants  of  the  study  .
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SELECTION  OF  PATIENTS:
INCLUSION  CRITERIA
Age  > 18  years
Evidence  of  cholestasis  ;
1.  Serum  bilirubin  > 2mg %
2. Serum  alkaline  phosphatase  more  than  twice  the  upper  limit  of
normal.
3. serum  alanine  transaminase  more  than  twice  the  upper  limit  of
normal.
4. Imaging  --  ultrasound  or  CT  abdomen  showing  dilated
common  bile  duct.
30   consecutive   patients   who   have   documented   evidence   of
obstructive  jaundice   who  have  undergone  ERCP   for  biliary
decompression  and  stenting  at   our  centre  during  the  study  period
were  included.
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EXCLUSION  CRITERIA
1. Age  less  than  18 years  .
                2. Absence  of  informed  consent  .
                3. Use  of  antibiotics  within  7  days  prior  to  ERCP  .
METHODS
After  ensuring  adequate  asepsis, biliary  cannulation  done  after
passing  a guidewire  under  fluoroscopic  guidance, around  10  ml  of
bile  is aspirated  before  injecting  contrast  and  the sample is  collected
and  inoculated  in  bile  broth  and  sent  for   microbiological  analysis.
Data collected were  recorded for further  work up.
Specific   mention   was  made  regarding   the   etiology   benign   or
malignant, stone, stricture  or  growth .
Nature    of   fluid   obtained,  findings   on   cholangiogram   if
available  are  documented.
History  of  previous  interventions ,number  of  attempts of
ERCP  are  all  recorded .
29
STATISTICAL    ANALYSIS
Statistical   analyses   were   carried   out   to   compare   continuous
variables    using   students   test.  Chi-squared   analysis   was   used   to
evaluate  categorical variables. A   P value  of  <0.05  was  considered
statistically   significant.  All   analysis   were   performed     using   SPSS
15.0 {SPSS.Inc.Chicago II}
P value
0 to 0.010         = ** =significant at 1% level
                                 (Highly significant)
0.011 to 0.050 = *   =significant at 5% level
                                        (significant)
>0.05           = no star =not significant at 5% level
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RESULTS AND STATISTICAL ANALYSIS
Descriptive Statistics
N Minimum
Maximu
m Mean
Std.
Deviation
Age in years 30 24 86 50.77 15.364
BILIRUBIN 30 1 12 4.30 2.813
SAP 30 520 1000 734.67 122.568
TC 30 7000 11000 8283.33 971.697
Valid N
(listwise) 30
Frequency Table
Sex
Frequency Percent
Valid
Percent
Valid Male 13 43.3 43.3
Female 17 56.7 56.7
Total 30 100.0 100.0
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ETIOLOGY
Frequency Percent
Valid
Percent
Valid Stone 17 56.7 56.7
St.M 2 6.7 6.7
St.B 6 20.0 20.0
Growth 5 16.7 16.7
Total 30 100.0 100.0
BILE C/S
Frequency Percent
Valid Positive 16 53.3
Negative 14 46.7
Total 30 100.0
32
E.COLI
Frequenc
y Percent
Valid Positive 4 13.3
Negative 16 53.3
Total 20 66.7
Missing System 10 33.3
Total 30 100.0
KLEBSILLA
Freque
ncy Percent
Valid Positive 8 26.7
Negative 22 73.3
Total 30 100.0
33
PSEUDOMONAS
Frequency Percent
Valid Positive 4 13.3
Negative 16 53.3
Total 20 66.7
Missing System 10 33.3
Total 30 100.0
CEFATAXIME
Frequency Percent
Valid S 10 33.3
R 6 20.0
Total 16 53.3
Missing System 14 46.7
Total 30 100.0
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AMIKACIN
Frequency Percent
Valid S 15 50.0
R 1 3.3
Total 16 53.3
Missing System 14 46.7
Total 30 100.0
PIPERACILLIN - TAZOBACTUM
Frequency Percent
Valid S 4 13.3
R 5 16.7
Total 9 30.0
Missing System 21 70.0
Total 30 100.0
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CEFTAZIDIME
Frequency Percent
Valid S 6 20.0
R 7 23.3
Total 13 43.3
Missing System 17 56.7
Total 30 100.0
CIPROFLOXACIN
Frequency Percent
Valid S 2 6.7
R 12 40.0
Total 14 46.7
Missing System 16 53.3
Total 30 100.0
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Crosstabs
ETIOLOGY * BILE C/S
Crosstab
BILE C/S Total
Positive Negative
ETIOLOGY Stone Count 9 8 17
% within
ETIOLO
GY
52.9% 47.1% 100.0%
% within
BILE C/S 56.3% 57.1% 56.7%
St.M Count 2 0 2
% within
ETIOLO
GY
100.0% .0% 100.0%
% within
BILE C/S 12.5% .0% 6.7%
St.B Count 1 5 6
% within
ETIOLO
GY
16.7% 83.3% 100.0%
% within
BILE C/S 6.3% 35.7% 20.0%
Growt
h
Count 4 1 5
% within
ETIOLO
GY
80.0% 20.0% 100.0%
% within
BILE C/S 25.0% 7.1% 16.7%
Total Count 16 14 30
% within
ETIOLO
GY
53.3% 46.7% 100.0%
% within
BILE C/S 100.0% 100.0% 100.0%
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ETIOLOGY * E.COLI
Crosstab
E.COLI Total
Positive Negative
ETIOLOGY Stone Count 3 9 12
% within
ETIOLOGY 25.0% 75.0% 100.0%
% within
E.COLI 75.0% 56.3% 60.0%
St.M Count 0 2 2
% within
ETIOLOGY .0% 100.0% 100.0%
% within
E.COLI .0% 12.5% 10.0%
St.B Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within
E.COLI 25.0% 6.3% 10.0%
Grow
th
Count 0 4 4
% within
ETIOLOGY .0% 100.0% 100.0%
% within
E.COLI .0% 25.0% 20.0%
Total Count 4 16 20
% within
ETIOLOGY 20.0% 80.0% 100.0%
% within
E.COLI 100.0% 100.0% 100.0%
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ETIOLOGY * KLEB
Crosstab
KLEB Total
Positive Negative
ETIOLOGY Stone Count 4 13 17
% within
ETIOLOGY 23.5% 76.5% 100.0%
% within
KLEB 50.0% 59.1% 56.7%
St.M Count 2 0 2
% within
ETIOLOGY 100.0% .0% 100.0%
% within
KLEB 25.0% .0% 6.7%
St.B Count 0 6 6
% within
ETIOLOGY .0% 100.0% 100.0%
% within
KLEB .0% 27.3% 20.0%
Growth Count 2 3 5
% within
ETIOLOGY 40.0% 60.0% 100.0%
% within
KLEB 25.0% 13.6% 16.7%
Total Count 8 22 30
% within
ETIOLOGY 26.7% 73.3% 100.0%
% within
KLEB 100.0% 100.0% 100.0%
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ETIOLOGY * PSEUDO
Crosstab
PSEUDOMONAS Total
Positive Negative
ETIOLOGY Stone Count 3 9 12
% within
ETIOLOGY 25.0% 75.0% 100.0%
% within
PSEUDO 75.0% 56.3% 60.0%
St.M Count 0 2 2
% within
ETIOLOGY .0% 100.0% 100.0%
% within
PSEUDO .0% 12.5% 10.0%
St.B Count 0 2 2
% within
ETIOLOGY .0% 100.0% 100.0%
% within
PSEUDO .0% 12.5% 10.0%
Growt
h
Count 1 3 4
% within
ETIOLOGY 25.0% 75.0% 100.0%
% within
PSEUDO 25.0% 18.8% 20.0%
Total Count 4 16 20
% within
ETIOLOGY 20.0% 80.0% 100.0%
% within
PSEUDO 100.0% 100.0% 100.0%
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ETIOLOGY * CEFATAXIME
Crosstab
CEFATAXIME Total
S R
ETIOLOGY Stone Count 4 5 9
% within
ETIOLOGY 44.4% 55.6% 100.0%
% within
CEFTAX
40.0% 83.3% 56.3%
St.M Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within
CEFTAX 10.0% 16.7% 12.5%
St.B Count 1 0 1
% within
ETIOLOGY 100.0% .0% 100.0%
% within
CEFTAX 10.0% .0% 6.3%
Growth Count 4 0 4
% within
ETIOLOGY 100.0% .0% 100.0%
% within
CEFTAX 40.0% .0% 25.0%
Total Count 10 6 16
% within
ETIOLOGY 62.5% 37.5% 100.0%
% within
CEFTAX 100.0% 100.0% 100.0%
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ETIOLOGY * AMIKACIN
Crosstab
AMIKACIN Total
S R
ETIOLOGY Stone Count 8 1 9
% within
ETIOLOGY 88.9% 11.1% 100.0%
% within
AMIK 53.3% 100.0% 56.3%
St.M Count 2 0 2
% within
ETIOLOGY 100.0% .0% 100.0%
% within
AMIK 13.3% .0% 12.5%
St.B Count 1 0 1
% within
ETIOLOGY 100.0% .0% 100.0%
% within
AMIK 6.7% .0% 6.3%
Growth Count 4 0 4
% within
ETIOLOGY 100.0% .0% 100.0%
% within
AMIK 26.7% .0% 25.0%
Total Count 15 1 16
% within
ETIOLOGY 93.8% 6.3% 100.0%
% within
AMIK 100.0% 100.0% 100.0%
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EIOLOGY * PIPERACILLIN- TAZOBACTUM
Crosstab
PIPERACILLIN
TAZOBACTUM Total
S R
ETIOLOGY Stone Count 2 1 3
% within
ETIOLOGY 66.7% 33.3% 100.0%
% within P -
TAZ 50.0% 20.0% 33.3%
St.M Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within P –
TAZ 25.0% 20.0% 22.2%
Growth Count 1 3 4
% within
ETIOLOGY 25.0% 75.0% 100.0%
% within P –
TAZ 25.0% 60.0% 44.4%
Total Count 4 5 9
% within
ETIOLOGY 44.4% 55.6% 100.0%
% within P –
TAZ 100.0% 100.0% 100.0%
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ETIOLOGY * CEFTAZIDIME
Crosstab
CEFTAZIDIME Total
S R
ETIOLOGY Stone Count 1 5 6
% within
ETIOLOGY 16.7% 83.3% 100.0%
% within
CEFTAZIDIME 16.7% 71.4% 46.2%
St.M Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within
CEFTAZIDIME 16.7% 14.3% 15.4%
St.B Count 1 0 1
% within
ETIOLOGY 100.0% .0% 100.0%
% within
CEFTAZIDIME 16.7% .0% 7.7%
Growt
h
Count 3 1 4
% within
ETIOLOGY 75.0% 25.0% 100.0%
% within
CEFTAZIDIME 50.0% 14.3% 30.8%
Total Count 6 7 13
% within
ETIOLOGY 46.2% 53.8% 100.0%
% within
CEFTAZIDIME 100.0% 100.0% 100.0%
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ETIOLOGY * CIPROFLOXACIN
Crosstab
CIPROFLOXACIN Total
S R
ETIO-
LOGY
Stone Count 0 9 9
% within
ETIOLOGY .0% 100.0% 100.0%
% within
CIPROFLOXACIN .0% 75.0% 64.3%
St.M Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within
CIPROFLOXACIN 50.0% 8.3% 14.3%
St.B Count 0 1 1
% within
ETIOLOGY .0% 100.0% 100.0%
% within
CIPROFLOXACIN .0% 8.3% 7.1%
Grow
th
Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within
CIPROFLOXACIN 50.0% 8.3% 14.3%
Total Count 2 12 14
% within
ETIOLOGY 14.3% 85.7% 100.0%
% within
CIPROFLOXACIN 100.0% 100.0% 100.0%
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Crosstabs
ETIOLOGY * Sex Crosstabulation
Sex Total
Male Female
ETIOLOGY Stone Count 4 13 17
% within
ETIOLOGY 23.5% 76.5% 100.0%
% within Sex 30.8% 76.5% 56.7%
St.M Count 1 1 2
% within
ETIOLOGY 50.0% 50.0% 100.0%
% within Sex 7.7% 5.9% 6.7%
St.B Count 5 1 6
% within
ETIOLOGY 83.3% 16.7% 100.0%
% within Sex 38.5% 5.9% 20.0%
Growth Count 3 2 5
% within
ETIOLOGY 60.0% 40.0% 100.0%
% within Sex 23.1% 11.8% 16.7%
Total Count 13 17 30
% within
ETIOLOGY 43.3% 56.7% 100.0%
% within Sex 100.0% 100.0% 100.0%
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E.COLI * CEFATAXIME
Crosstab
CEFATAXIME Total
S R
E.COLI Positive Count 2 2 4
% within
E.COLI 50.0% 50.0% 100.0%
% within
CEFATAXIME 20.0% 33.3% 25.0%
Negative Count 8 4 12
% within
E.COLI 66.7% 33.3% 100.0%
% within
CEFATAXIME 80.0% 66.7% 75.0%
Total Count 10 6 16
% within
E.COLI 62.5% 37.5% 100.0%
% within
CEFATAXIME 100.0% 100.0% 100.0%
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E.COLI * AMIKACIN
Crosstab
AMIKACIN Total
S R
E.COLI Positive Count 4 0 4
% within
E.COLI 100.0% .0% 100.0%
% within
AMIKACIN 26.7% .0% 25.0%
Negative Count 11 1 12
% within
E.COLI 91.7% 8.3% 100.0%
% within
AMIKACIN 73.3% 100.0% 75.0%
Total Count 15 1 16
% within
E.COLI 93.8% 6.3% 100.0%
% within
AMIKACIN 100.0% 100.0% 100.0%
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E.COLI * PIPERACILLIN - TAZOBACTUM
Crosstab
PIPTAZ Total
S R
E.COLI Negative Count 4 5 9
% within
E.COLI 44.4% 55.6% 100.0%
% within
 P - TAZ
100.0% 100.0% 100.0%
Total Count 4 5 9
% within
E.COLI 44.4% 55.6% 100.0%
% within
P – TAZ
100.0% 100.0% 100.0%
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E.COLI * CEFTAZIDIME
Crosstab
FORTUM Total
S R
E.COLI Positive Count 1 2 3
% within E.COLI 33.3% 66.7% 100.0%
% within
CEFTAZIDIME 16.7% 28.6% 23.1%
Negative Count 5 5 10
% within E.COLI 50.0% 50.0% 100.0%
% within
CEFTAZIDIME 83.3% 71.4% 76.9%
Total Count 6 7 13
% within E.COLI 46.2% 53.8% 100.0%
% within
CEFTAZIDIME 100.0% 100.0% 100.0%
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E.COLI * CIPROFLOXACIN
Crosstab
CIPROFLOXA
CIN Total
S R
E.COLI Positive Count 0 4 4
% within E.COLI .0% 100.0% 100.0%
% within
CIPROFLOXACIN .0% 33.3% 28.6%
Negative Count 2 8 10
% within E.COLI 20.0% 80.0% 100.0%
% within
CIPROFLOXACIN 100.0% 66.7% 71.4%
Total Count 2 12 14
% within E.COLI 14.3% 85.7% 100.0%
% within
CIPROFLOXACIN 100.0% 100.0% 100.0%
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KLEB * CIFRAN
Crosstab
CIFRAN Total
S R
KLEB Positive Count 2 5 7
% within
KLEB 28.6% 71.4% 100.0%
% within
CIFRAN 100.0% 41.7% 50.0%
Negativ
e
Count 0 7 7
% within
KLEB .0% 100.0% 100.0%
% within
CIFRAN .0% 58.3% 50.0%
Total Count 2 12 14
% within
KLEB 14.3% 85.7% 100.0%
% within
CIFRAN 100.0% 100.0% 100.0%
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PSEUDO * TAXIM
Crosstab
TAXIM Total
S R
PSEUDO Positive Count 2 2 4
% within
PSEUDO 50.0% 50.0% 100.0%
% within
TAXIM 20.0% 33.3% 25.0%
Negative Count 8 4 12
% within
PSEUDO 66.7% 33.3% 100.0%
% within
TAXIM 80.0% 66.7% 75.0%
Total Count 10 6 16
% within
PSEUDO 62.5% 37.5% 100.0%
% within
TAXIM 100.0% 100.0% 100.0%
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PSEUDO * AMIK
Crosstab
AMIK Total
S R
PSEUDO Positive Count 4 0 4
% within
PSEUDO 100.0% .0% 100.0%
% within
AMIK 26.7% .0% 25.0%
Negative Count 11 1 12
% within
PSEUDO 91.7% 8.3% 100.0%
% within
AMIK 73.3% 100.0% 75.0%
Total Count 15 1 16
% within
PSEUDO 93.8% 6.3% 100.0%
% within
AMIK 100.0% 100.0% 100.0%
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PSEUDO * PIPTAZ
Crosstab
PIPTAZ Total
S R
PSEUDO Positive Count 2 1 3
% within
PSEUDO 66.7% 33.3% 100.0%
% within
PIPTAZ 50.0% 20.0% 33.3%
Negative Count 2 4 6
% within
PSEUDO 33.3% 66.7% 100.0%
% within
PIPTAZ 50.0% 80.0% 66.7%
Total Count 4 5 9
% within
PSEUDO 44.4% 55.6% 100.0%
% within
PIPTAZ 100.0% 100.0% 100.0%
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PSEUDO * FORTUM
Crosstab
FORTUM Total
S R
PSEUDO Positive Count 1 3 4
% within
PSEUDO 25.0% 75.0% 100.0%
% within
FORTUM 16.7% 42.9% 30.8%
Negative Count 5 4 9
% within
PSEUDO 55.6% 44.4% 100.0%
% within
FORTUM 83.3% 57.1% 69.2%
Total Count 6 7 13
% within
PSEUDO 46.2% 53.8% 100.0%
% within
FORTUM 100.0% 100.0% 100.0%
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PSEUDO * CIFRAN
Crosstab
CIFRAN Total
S R
PSEUDO Positive Count 0 4 4
% within
PSEUDO .0% 100.0% 100.0%
% within
CIFRAN .0% 33.3% 28.6%
Negative Count 2 8 10
% within
PSEUDO 20.0% 80.0% 100.0%
% within
CIFRAN 100.0% 66.7% 71.4%
Total Count 2 12 14
% within
PSEUDO 14.3% 85.7% 100.0%
% within
CIFRAN 100.0% 100.0% 100.0%
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Crosstabs
ETIOLOGY * BILE C/S Crosstabulation
BILE C/S Total
Positive Negative
ETIOLOGY B Count 10 13 23
% within
ETIOLOG
Y
43.5% 56.5% 100.0%
% within
BILE C/S 62.5% 92.9% 76.7%
M Count 6 1 7
% within
ETIOLOG
Y
85.7% 14.3% 100.0%
% within
BILE C/S 37.5% 7.1% 23.3%
Total Count 16 14 30
% within
ETIOLOG
Y
53.3% 46.7% 100.0%
% within
BILE C/S 100.0% 100.0% 100.0%
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BILE C/S
Observed N Expected N Residual
Positive 16 15.0 1.0
Negative 14 15.0 -1.0
Total 30
30   Consecutive  cases  who   have   undergone   ERCP     at  our
institution,  and   successful   biliary   cannulation    were  studied  .Among
them  ,13  were  males  43.3%  and  17 (56.7%  were  females .
Mean  age  was  50.77 with  standard  deviation  of  15 .364  .
Among   the  30  cases  ,23  have  benign  disease
and  7 have  malignant  disease.
17 patients  had  common  bile  duct  stones (56.7% )
5  patients  had  malignant  growth   .(16.7 % )
6  had  benign  biliary  stricture  (20  % )
2  had   malignant  biliary  stricture  .( 6.7 )
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Bile   culture   was   positive   in   16   patients   .(53  .3%  )  and
negative  in  14  patients  .(.46 .7 % ) .Benign -10 malignant-6 .(p-value
<0.05 ).
Almost   all positive  bile  cultures   grew  gram  negative  bacilli.9
out of  16  have  grown  Klebsiella .( p-value-significant at 5% level )
4  cultures were  positive  for  E.coli .
Pseudomonas  was grown  in  3  cultures  .
Almost  all  except  one  growth  on  culture  were  monomicrobial.
Most   of   the   organisms   grown   in    bile  were   sensitive    to
Amikacin , cefotaxime  and  ceftazidime  ( p-value-not significant )
Most  of  them  were  resistant  to  ciprofloxacin .
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DISCUSSION
In   our   study  ,we   found    that   asymptomatic   bacterobilia   was
more  common  than  earlier  reports.(53.3 %).
Variation  with  underlying  pathology  is  common.
Among   the   risk   factors  ,common   bile   duct   stones    are  the
commonest . (56.7%  sensitive ).
Only    20  %  of   benign   biliary   stricture    had   a   positive   bile
culture .
Malignant  biliary  strictures   showed  6 .7 % positivity.
Micro-organisms   grown  in  bile  culture  were predominantly
gram negative  bacilli  .
Klebsiella was  predominant  E .coli   comes  the  next  .
Unusual   bacteria   like   pseudomonas   and   staphylococci   may
grow in culture  and  may  be  due  to  iatrogenic introduction  of  bacteria
by  poorly  sterilized  endoscope   or  a  percutaneous  drain  .Incidence
ranges  from   0  to  25  % and  may  reflect  prior  biliary  intervention  or
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antibiotic   usage   .In   our   case,  no   such   history   available   in   the
subgroup  with  pseudomonas   positivity  by  culture.
It  is  noticeable  that  bacterobilia  is  found  in  patients without
biliary   sepsis  .  Obstruction    leads    to   sepsis  ,as   increase   in   biliary
pressure   induces   regurgitation   of   bile.  The   biliary   contents   reflux
into sinusoids  when  biliary pressure increases to 25cm of water.
Regarding  treatment  with  antibiotics  ,studies  have  shown  that
antibiotics   used   should   be   active   against    gram   negative   bacilli.
Quinolones   are   preferred   because   they   are   effective   when   given
orally .They effectively  penetrate  in  obstructed  biliary  tree.
In   our study  most   organisms  grown  on  culture  are  resistant
to ciprofloxacin.  (E.coli-100  % , Klebsiella-71 .4 % pseudomonas
-100 % )
Most  organisms  responded  to  cefotaxim  ,ceftazidine  and
amikacin.
Patients   with   CBD stone  disease   have   a   higher   incidence   of
bacterobilia   .  Previous   studies    around   84  %   in   a   study    of   70
patients   (Keighley   et   al  ),  83  %  in   a   study    of   545   patients
( Maluenda  et al  ) and  82  %   in  a  study   of  65 patients .( Pitt  et  al )
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Patients   with  malignant  obstruction   have  lesser incidence  of
bacterobilia , Previous  studies  also  confirm the  same.
(46 % Pitt et al  .,30 % Keighley  et al  .,21 % Maluenda  et al )
Benign   biliary   strictures   have   a  higher   incidence    of
bacterobilia  in  earlier  studies   which are  consistent with  our  findings
Pre-operative  biliary  drainage  in  malignant   obstruction     could  be
beneficial   in   patients   with   sepsis   ,co-agulation   abnormalities   and
malnutrition  .( Dig  .surg  2001  18  84—89 ).
Pre  -operative  biliary  drainage  is   associated   high       incidence
of   bacterobilia     and   fungal    colonisation   .  (Alim .    pharma cology
2009   Jethwa  et  all ).
None   of   the   patients   in    our   study   presented   with   clinico
imaging    suggestive   of   cholangitis  .None   had   previous   biliary
intervention. Bacterobilia is present  only in  obstructed  biliary  system
.Bile is  usually sterile   in  normal individuals  .  Hatfield et  al 19 observed
0% growth  in  a study of  10 patients  in normal  individuals .Csenda et
al16 also   observed  0 % growth in normal bile in a study of  20 patients
.Nielson   and   Justesen    et  al17 observed  0 % growth in unobstructed
bile in a study of 38  patients  .
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Bacterobilia  is commonly present  in  obstructed  biliary  system
due   to   common    bile   duct   stone   and   is   documented   in   various
studies  .Keighly   et al24  in a  study  of  70 patients with  common bile
duct   stone  disease    observed  bacterobilia   in  84%  of   cases .Pitt  et
al 25observed  82 % bacterobilia  in a study of  65 patients .
Maluenda et al 26observed  83 % bacterobilia   in  545 patients
studied .Kosowski  et al27 in a study of   34 patients  observed  82 % of
bacterobilia  in  stone  disease   .Leung et al 28in a study of  896  patients
with  stone  disease observed  64 % of  bacterobilia  .Landau  et  al 29in
his  study  of    436   patients  with   stone   disease   observed     61%  of
bacterobilia .Wells et al  (30 ) in his study  of 73 patients of stone disease
observed  73 % of  bacterobilia .
Recent    studies  by  Ahamed et al50 quoted in GI endoscopy 2010
also observed    positive  bile cultures in 18 out of  20  cases with   CBD
stone  disease.
Sahu  et al52 in their study  published  in  IJG  sept 2011 observed
bacterobilia  in  88  of  95  patients  studied.
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Bacterobilia in malignant  obstruction   were comparatively  less
than   those   observed  with   stone   disease,as  observed   in   previous
studies.
Pitt  et al  -    46% in  35 patients  studied.
Well et al   31 % in 16 patients studied.
Keighley et al   -  30% in 102 patients  studied.
Mannala et al  -  27 % in  91  patients31
Nielson and  Justesen   0 % in 28  patients.
Our   study  also   observed   the   same  finding   with   bacterobilia
predominant   in  benign   biliary   obstruction  ,  most   commonly   due   to
common  bile  duct  stone  disease .
Growth  pattern  in  bile  culture  varied in  different  studies
In  a  study   published   in   Alimentary   pharmacological   therapy
1995, the microbiological profile observed are as follows.
E .coli  55%
Klebsiella 20- 30 %
Proteus -5 %
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Salmonella -0-3%
Pseudomonas –0-25%
Pitts  et  al   of 25 patients
E coli -52 %
Klebsiella -34%
Pseudomonas -25%
Malusuda  et al –of 230 patients
Ecoli  52 %
Klebsiella 14 %
Pseudomonas   0%
Recent  studies by  Sahu et al 52and Ahamed et al50 also confirmed
E.coli   as  a  predominant  organism  grown  in  bile   culture  .  But  in  our
study, the predominant organism grown was klebsiella. (9 out of  16
positive cases. whereas E .coli was grown in 4 cultures.
Antibiotic  sensitivity  is  consistent  with   earlier  studies  in that
most of  them  respond   to cephalosporins  and amikacin. But  in
contrast  to   earlier   studies,  sensitivity   to   ciprofloxacin   was   not
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consistent  .In  fact  ,most  of   the   organisms   grown  on   culture   are
resistant  to  ciprofloxacin.
Gram positive bacteria and anaerobes  were not  grown  in culture
in  our  study.
Thawee  Ratanachu  et al47, in a study published in  world journal
of gastroenterology  2007, studied  the role of  ciprofloxacin  in patients
with cholestasis  after  ERCP. They observed that ciprofloxacin was
effective  in   the study  population .
An  Indian study  conducted by  Shivaprakash  et al  reported  high
resistance to  ciprofloxacin, correlates with our  observation 53
Aggarwal  et  al   conducted  a  study   in2006   in  patients  with
cholangitis.70% of  patients   of   175  studied  had   common  bile  duct  as
etiology54
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21 % had  malignancy .
Shimada  et al   in 1981 ,studied  23 bile  cultures    in aged  population
.All had a   positive bile  culture .Out of them ,15 yielded both aerobic
and  anaerobic  growth and 8 had only anaerobic growth
.E.coli,klebsiella,enterococci and bacteroides fragilis  were isolated .He
also suggested  that  treatment  of  anaerobic infections in the elderly is
mandatory .
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CONCLUSION
Bacterobilia   is  common  in  obstructed  biliary  system   and are
usually asymptomatic.
It   is   more   common   in   benign  biliary   obstruction   than
malignant  biliary  obstruction.
Most   common   risk   factor  for   bacterobilia    observed   in   our
study  is  common  bile  duct  stone.
Other  risk  factors  identified in our study  include  malignant
growth  and biliary  strictures.
Biliary   decompression  with   stent   placement    helps   in
symptomatic relief.
Bile   culture  is    useful   in   early   diagnosis   and   prevention   of
complications.
Gram negative  bacilli infection  is  very  common in obstructed
biliary  system.
Klebsiella  is  the  commonest  organism  grown  in our  study.
71
Escherichia.coli is  the second  commonest organism  isolated from
bile culture in  our  study.
Pseudomonas aeroginosa is the  third commonest organism   grown
in our study.
Microbiological  sensitivity pattern  is different  in  our  study.
Most of  them  respond ed to  third  generation  cephalosporins  and
amikacin and resistance  to ciprofloxacin  was common.   In conclusion,
routine   bile   cultures  done  for   all  patients    during   ERCP in   patients
presenting with  biliary obstruction    can help in predicting  early  biliary
sepsis  which   will   respond  to   antibiotics    and   prevent   dreaded
complications.
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PROFORMA
 DDHD No
ERCP No
Name of the patient:
Age and sex:
Presenting symptoms-
fever, abdominal pain, pruritus,
Loss of appetite and weight, jaundice,altered sensorium
Past history of jaundice,ERCP,HT,DM,CAD,Abdominal surgery,drug
intake,organ transplantation,
Exposure to STD,alcohol consumption,smoking.
Urine routine, complete haemogram, blood urea, blood sugar, LFT
Chest x-ray, USG abdomen,
CT abdomen, MRCP
Blood culture and sensitivity;Bile culture and sensitivity
Present and previous ERCP-indications and complications
